Latest Blog Posts Tagged "Alpha-Synuclein"
July 10, 2017
Five projects targeting alpha-synuclein are in clinical trials with more preparing for testing.
June 29, 2017
MJFF scientist speaks to "Nature Reviews Drug Discovery" about alpha-synuclein research progress in Parkinson's disease.
June 22, 2017
MJFF-funded researchers published on a connection between the key Parkinson's protein alpha-synuclein and the immune system. This finding may point to a new way to stop or slow disease.
May 02, 2017
A new study builds on the theory that PD could start in the gut, rather than the brain.
April 13, 2017
Researchers haven't yet determined the optimal location or method to sample alpha-synuclein. Learn how MJFF's Systemic Synuclein Sampling Study is hoping to change this.
March 20, 2017
A recently published study has revealed differences in gut bacteria in those with Parkinson's disease based on their medications and geographic locations, adding to our growing knowledge.
February 14, 2017
This study is a major step for PD research as it is the first drug trial where one's genetic information determines eligibility and is testing a potential therapy to slow or stop disease progression.
January 30, 2017
Joann, a person living with Parkinson's, shares her experience participating in the Systemic Synuclein Sampling Study (S4).
November 11, 2016
Dr. Jamie Eberling, PhD, dicusses alpha-synuclein, a protein that clumps in brain cells of nearly everyone with Parkinson's disease.
November 10, 2016
The trial showed the therapy is safe and tolerable and that the drug gets into the central nervous system well and reduces levels of alpha-synuclein in blood serum. Phase II expected to begin in 2017.